Supplemental Annuity Collective Trust (SACT) of New Jersey’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Supplemental Annuity Collective Trust (SACT) of New Jersey’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,000	Closed	-$644K	–	221
2023 Q1	$644K	Buy	+6,000	New	+$691K	0.25%	114

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Supplemental Annuity Collective Trust (SACT) of New Jersey's RXDX Position: Q2 2023 in Review

Supplemental Annuity Collective Trust (SACT) of New Jersey sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 6,000 shares — an estimated $644K sold.

Supplemental Annuity Collective Trust (SACT) of New Jersey first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $644K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Supplemental Annuity Collective Trust (SACT) of New Jersey reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Supplemental Annuity Collective Trust (SACT) of New Jersey sold 6,000 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $644K.
Supplemental Annuity Collective Trust (SACT) of New Jersey first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Supplemental Annuity Collective Trust (SACT) of New Jersey's Prometheus Biosciences, Inc. Common Stock position peaked at $644K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Supplemental Annuity Collective Trust (SACT) of New Jersey's 13F filing for Q2 2023, filed 2 Aug 2023.